[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 113, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 57, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 594612, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 339819, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 48, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 53, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 339300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 63, "title": "Chief Commercial Officer, President of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 469802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 68, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 47, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. June S. Almenoff FACP, M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.5351, "open": 0.54, "dayLow": 0.54, "dayHigh": 0.56, "regularMarketPreviousClose": 0.5351, "regularMarketOpen": 0.54, "regularMarketDayLow": 0.54, "regularMarketDayHigh": 0.56, "beta": 3.464, "forwardPE": 18.326666, "volume": 2460234, "regularMarketVolume": 2460234, "averageVolume": 1854408, "averageVolume10days": 1167700, "averageDailyVolume10Day": 1167700, "bid": 0.5457, "bidSize": 3100, "askSize": 800, "marketCap": 16330709, "fiftyTwoWeekLow": 0.257, "fiftyTwoWeekHigh": 7.6, "priceToSalesTrailing12Months": 0.45686695, "fiftyDayAverage": 0.79462, "twoHundredDayAverage": 1.01315, "currency": "USD", "enterpriseValue": 697876544, "profitMargins": 0.32374, "floatShares": 1199542900, "sharesOutstanding": 29703000, "sharesShort": 376153, "sharesShortPriorMonth": 1114157, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0127, "heldPercentInstitutions": 0.06702, "shortRatio": 0.53, "shortPercentOfFloat": 0.0127, "bookValue": 1.086, "priceToBook": 0.5062615, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1688083200, "netIncomeToCommon": 11572000, "trailingEps": -8.0, "forwardEps": 0.03, "enterpriseToRevenue": 19.524, "enterpriseToEbitda": -28.996, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RDHL", "underlyingSymbol": "RDHL", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "firstTradeDateEpochUtc": 1357569000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "55b47776-7c51-3ec7-bc27-c300c5d6081d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.5498, "targetHighPrice": 760.0, "targetLowPrice": 760.0, "targetMeanPrice": 760.0, "targetMedianPrice": 760.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 7014000, "totalCashPerShare": 0.005, "ebitda": -24068000, "totalDebt": 2284000, "quickRatio": 0.352, "currentRatio": 0.96, "totalRevenue": 35745000, "debtToEquity": 65.802, "revenuePerShare": 14.516, "returnOnAssets": -0.1717, "freeCashflow": -38703624, "operatingCashflow": -26224000, "revenueGrowth": -0.902, "grossMargins": 0.42742002, "ebitdaMargins": -0.67332, "operatingMargins": -2.45434, "financialCurrency": "USD", "trailingPegRatio": null}]